Inhibitors of C5 complement enhance vaccinia virus oncolysis. - Wikidata - awgldk - TriplyDB

Inhibitors of C5 complement enhance vaccinia virus oncolysis.

Inhibitors of C5 complement enhance vaccinia virus oncolysis.

http://www.wikidata.org/entity/Q33768177

about

Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives Oncolytic Poxviruses.Successive site translocating inoculation potentiates DNA/recombinant vaccinia vaccination Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.Oncolytic viruses and their application to cancer immunotherapy Oncolytic Immunotherapy for Treatment of Cancer.Prospects for combined use of oncolytic viruses and CAR T-cells.Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer.Potential of oncolytic viruses in the treatment of multiple myeloma.

P2860

Q33679505-7D4C63A2-2D57-43F5-B71D-3134FCF7D824 Q35234349-37872CD5-0705-4E14-A56A-7AC2B919C57E Q36369631-51BCE883-411E-421E-9D77-16B15A1FA2E5 Q36756690-43717BF1-0478-4A9C-B4CB-7789D5ADB0BF Q37256174-6777457F-C7D3-4A94-9D6D-A55D87AEFFBB Q38207011-C29C36DC-04D9-4B65-A2A8-A611B3D6C391 Q38848223-6E06F074-18AC-4A1F-8F17-792312C02215 Q47103891-3AD8C9D9-2C87-43F0-82DF-DE26E9696BDE Q47148148-0F1B9BFF-FA07-43C6-9EBB-236002D24435 Q52674773-DF8AA37A-B78B-480C-9FAF-A2D4C068196D

P2860

Inhibitors of C5 complement enhance vaccinia virus oncolysis.

http://www.wikidata.org/entity/Q33768177

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Inhibitors of C5 complement enhance vaccinia virus oncolysis.

@ast

Inhibitors of C5 complement enhance vaccinia virus oncolysis.

@en

type

label

Inhibitors of C5 complement enhance vaccinia virus oncolysis.

@ast

Inhibitors of C5 complement enhance vaccinia virus oncolysis.

@en

prefLabel

Inhibitors of C5 complement enhance vaccinia virus oncolysis.

@ast

Inhibitors of C5 complement enhance vaccinia virus oncolysis.

@en

P1433

Q33768177-C34CE1F9-9897-4D57-9642-A8A5EA5D4051

P1476

Q33768177-BA889ADF-471D-4206-AE56-55F8FE51CC04

P2093

Q33768177-2ECB72A9-7008-449D-9C95-08E35ED1EF91

Q33768177-53DA6720-E158-4014-BDBC-3BFD6AEB41A8

Q33768177-8D493243-CB4D-4D70-B3E2-D8AA7CD571F5

Q33768177-BDBB3C4C-267B-445E-8011-7938FF6D7B86

Q33768177-E0B12F8B-E563-4DB2-9AFE-CE2AC82B5DF9

Q33768177-F3C2C22B-61C2-436D-9DBC-5EDF7525AD98

P2860

Q33768177-028AE0FF-3673-41A3-963A-39CE576096A6

Q33768177-147B6AB1-BF20-4A53-B52E-078888E4DAEB

Q33768177-1ADBB80D-765D-4727-8858-F85B5CC8ADCF

Q33768177-1AED9D40-0136-43EF-90A6-EB55F63A4CC7

Q33768177-21B4A27C-AB21-4E81-8855-FC75780B4326

Q33768177-261E66F6-BC18-4643-A050-830D7B1D24C0

Q33768177-291145A5-659F-47F7-9406-5617B758A44B

Q33768177-2A17BC8A-A541-40B9-B2E1-E99369630FFF

Q33768177-404A9A28-6207-4625-AF7B-35E7C032BEB6

Q33768177-410622E7-90CF-49C0-97BD-782CCF8D30F5

P2888

Q33768177-3D280078-2295-4040-A8E3-3984B7B9FE42

P304

Q33768177-C651B577-A911-4BD6-9B5B-EEADAF4AA86D

P31

Q33768177-33163071-BC87-48C9-A4CA-21F5735DD80D

P356

Q33768177-F4703FE1-C764-4760-90E0-C7AD93442E4C

P433

Q33768177-B818BD76-AAF6-4670-80BB-E6ADF5A1CBA5

P478

Q33768177-6855737D-1413-439A-AD17-8E9ED9D59E9E

P577

Q33768177-53DAE907-3BF7-4363-B8F7-FE0B3B2C1F11

P5875

Q33768177-4F450D8D-4BA8-4326-B504-8EE144F42875

P6179

Q33768177-10B1D730-51F0-4AF6-8B15-F540AF8728E5

P698

Q33768177-02B0DA08-4D25-48B2-95DB-18053DEBE09D

P932

Q33768177-F3099FE4-1437-4AF0-81AE-42D12B6E9DFF

P356

P1433

Cancer Gene Therapy

P1476

Inhibitors of C5 complement enhance vaccinia virus oncolysis.

@en

P2093

D L Bartlett

http://www.w3.org/2001/XMLSchema#string

D Magge

http://www.w3.org/2001/XMLSchema#string

L Francis

http://www.w3.org/2001/XMLSchema#string

M E O'Malley

http://www.w3.org/2001/XMLSchema#string

R Ravindranathan

http://www.w3.org/2001/XMLSchema#string

Z S Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Compstatin: a complement inhibitor on its way to clinical application

Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity

Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus

Reflex control of immunity

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Surviving mousepox infection requires the complement system

Complement evasion by human pathogens.

Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.

Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses

Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.

P2888

P304

342-350

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CGT.2013.26

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236675171

http://www.w3.org/2001/XMLSchema#string

P6179

1026375637

http://www.w3.org/2001/XMLSchema#string

P698

23661042

http://www.w3.org/2001/XMLSchema#string

P932

4060830

http://www.w3.org/2001/XMLSchema#string